These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

370 related items for PubMed ID: 26822379

  • 1. Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer.
    Sheng J, Fang W, Yu J, Chen N, Zhan J, Ma Y, Yang Y, Huang Y, Zhao H, Zhang L.
    Sci Rep; 2016 Jan 29; 6():20090. PubMed ID: 26822379
    [Abstract] [Full Text] [Related]

  • 2. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.
    Cooper WA, Tran T, Vilain RE, Madore J, Selinger CI, Kohonen-Corish M, Yip P, Yu B, O'Toole SA, McCaughan BC, Yearley JH, Horvath LG, Kao S, Boyer M, Scolyer RA.
    Lung Cancer; 2015 Aug 29; 89(2):181-8. PubMed ID: 26024796
    [Abstract] [Full Text] [Related]

  • 3. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
    Schmidt LH, Kümmel A, Görlich D, Mohr M, Bröckling S, Mikesch JH, Grünewald I, Marra A, Schultheis AM, Wardelmann E, Müller-Tidow C, Spieker T, Schliemann C, Berdel WE, Wiewrodt R, Hartmann W.
    PLoS One; 2015 Aug 29; 10(8):e0136023. PubMed ID: 26313362
    [Abstract] [Full Text] [Related]

  • 4. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
    Tokito T, Azuma K, Kawahara A, Ishii H, Yamada K, Matsuo N, Kinoshita T, Mizukami N, Ono H, Kage M, Hoshino T.
    Eur J Cancer; 2016 Mar 29; 55():7-14. PubMed ID: 26771872
    [Abstract] [Full Text] [Related]

  • 5. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
    Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, Braiteh F, Waterkamp D, He P, Zou W, Chen DS, Yi J, Sandler A, Rittmeyer A, POPLAR Study Group.
    Lancet; 2016 Apr 30; 387(10030):1837-46. PubMed ID: 26970723
    [Abstract] [Full Text] [Related]

  • 6. PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors.
    Meniawy TM, Lake RA, McDonnell AM, Millward MJ, Nowak AK.
    Lung Cancer; 2016 Mar 30; 93():9-16. PubMed ID: 26898608
    [Abstract] [Full Text] [Related]

  • 7. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.
    Kim S, Kim MY, Koh J, Go H, Lee DS, Jeon YK, Chung DH.
    Eur J Cancer; 2015 Nov 30; 51(17):2698-707. PubMed ID: 26329973
    [Abstract] [Full Text] [Related]

  • 8. Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer.
    Guo L, Song P, Xue X, Guo C, Han L, Fang Q, Ying J, Gao S, Li W.
    J Immunother; 2019 Nov 30; 42(6):215-220. PubMed ID: 31145232
    [Abstract] [Full Text] [Related]

  • 9. Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer.
    Ishii H, Azuma K, Kawahara A, Yamada K, Imamura Y, Tokito T, Kinoshita T, Kage M, Hoshino T.
    J Thorac Oncol; 2015 Mar 30; 10(3):426-30. PubMed ID: 25384063
    [Abstract] [Full Text] [Related]

  • 10. Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer.
    Shin J, Chung JH, Kim SH, Lee KS, Suh KJ, Lee JY, Kim JW, Lee JO, Kim JW, Kim YJ, Lee KW, Kim JH, Bang SM, Lee JS.
    Cancer Res Treat; 2019 Jul 30; 51(3):1086-1097. PubMed ID: 30428640
    [Abstract] [Full Text] [Related]

  • 11. Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma.
    Del C Monroig-Bosque P, Driver B, Morales-Rosado JA, Deavers M, Tacha D, Bernicker E, Cagle PT, Miller RA.
    Arch Pathol Lab Med; 2018 Nov 30; 142(11):1388-1393. PubMed ID: 29431467
    [Abstract] [Full Text] [Related]

  • 12. Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.
    Calles A, Liao X, Sholl LM, Rodig SJ, Freeman GJ, Butaney M, Lydon C, Dahlberg SE, Hodi FS, Oxnard GR, Jackman DM, Jänne PA.
    J Thorac Oncol; 2015 Dec 30; 10(12):1726-35. PubMed ID: 26473645
    [Abstract] [Full Text] [Related]

  • 13. Altered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma.
    Song Z, Yu X, Zhang Y.
    Lung Cancer; 2016 Sep 30; 99():166-71. PubMed ID: 27565935
    [Abstract] [Full Text] [Related]

  • 14. Clinicopathologic correlation of programmed death ligand-1 expression in non-small cell lung carcinomas: A report from India.
    Vallonthaiel AG, Malik PS, Singh V, Kumar V, Kumar S, Sharma MC, Mathur S, Arava S, Guleria R, Jain D.
    Ann Diagn Pathol; 2017 Dec 30; 31():56-61. PubMed ID: 29146060
    [Abstract] [Full Text] [Related]

  • 15. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
    Kim MY, Koh J, Kim S, Go H, Jeon YK, Chung DH.
    Lung Cancer; 2015 Apr 30; 88(1):24-33. PubMed ID: 25662388
    [Abstract] [Full Text] [Related]

  • 16. A Minimum Of 100 Tumor Cells in a Single Biopsy Sample Is Required to Assess Programmed Cell Death Ligand 1 Expression in Predicting Patient Response to Nivolumab Treatment in Nonsquamous Non-Small Cell Lung Carcinoma.
    Naito T, Udagawa H, Sato J, Horinouchi H, Murakami S, Goto Y, Kanda S, Fujiwara Y, Yamamoto N, Zenke Y, Kirita K, Matsumoto S, Yoh K, Niho S, Motoi N, Ohe Y, Ishii G, Goto K.
    J Thorac Oncol; 2019 Oct 30; 14(10):1818-1827. PubMed ID: 31260834
    [Abstract] [Full Text] [Related]

  • 17. PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer.
    Ikeda S, Okamoto T, Okano S, Umemoto Y, Tagawa T, Morodomi Y, Kohno M, Shimamatsu S, Kitahara H, Suzuki Y, Fujishita T, Maehara Y.
    J Thorac Oncol; 2016 Jan 30; 11(1):62-71. PubMed ID: 26762740
    [Abstract] [Full Text] [Related]

  • 18. Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer.
    Han JJ, Kim DW, Koh J, Keam B, Kim TM, Jeon YK, Lee SH, Chung DH, Heo DS.
    Clin Lung Cancer; 2016 Jul 30; 17(4):263-270.e2. PubMed ID: 26707383
    [Abstract] [Full Text] [Related]

  • 19. A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.
    Takada K, Toyokawa G, Okamoto T, Shimokawa M, Kozuma Y, Matsubara T, Haratake N, Akamine T, Takamori S, Katsura M, Shoji F, Oda Y, Maehara Y.
    Clin Lung Cancer; 2017 Sep 30; 18(5):572-582.e1. PubMed ID: 28318951
    [Abstract] [Full Text] [Related]

  • 20. Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung Cancer.
    Igawa S, Sato Y, Ryuge S, Ichinoe M, Katono K, Hiyoshi Y, Otani S, Nagashio R, Nakashima H, Katagiri M, Sasaki J, Murakumo Y, Satoh Y, Masuda N.
    Oncology; 2017 Sep 30; 92(5):283-290. PubMed ID: 28222447
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.